Fundamental and clinical studies on pipemidic acid were made with the following results.
1. Pipemidic acid was more potent than piromidic acid and nalidixic acid in in vitro activity against Escherichia coli, Klebsiella and Pseudomonas aeruginosa, and as potent as carbenicillin against Pseudomonas aeruginosa.
2. Some of nalidixic acid-resistant Escherichia coli was found to be sensitive to pipemidic acid.
3. Five of 9 cases were successfully treated with pipemidic acid, the efficacy rate being 55. 5%.
4. Except for 1 case complaining stomachache, no side effect was observed. No abnormality was found as to liver and kidney functions.
Pipemidic acid having more potent antibacterial activity than nalidixic acid is considered to be a promising drug especially for urinary tract infections.
